Acurx Pharmaceuticals, Inc.
ACXP
$3.10
$0.3211.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.49% | -8.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.29% | -10.62% | |||
| Operating Income | 20.29% | 10.62% | |||
| Income Before Tax | 20.80% | 11.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.80% | 11.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.80% | 11.29% | |||
| EBIT | 20.29% | 10.62% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 40.61% | 35.05% | |||
| Normalized Basic EPS | 40.62% | 35.05% | |||
| EPS Diluted | 40.61% | 35.05% | |||
| Normalized Diluted EPS | 40.62% | 35.05% | |||
| Average Basic Shares Outstanding | 33.37% | 36.59% | |||
| Average Diluted Shares Outstanding | 33.37% | 36.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||